Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ADBE +14.1%, FRHC +2.8%
Other news:
- MOLN +11.6% (Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024)
- ZKH +11.2% (authorizes new $50 mln share repurchase program)
- BOOM +9% (Steel Connect affirms 9.8% active stake; sent non-binding proposal to acquire shares at $16.50 per share in cash on May 31)
- BITF +8.2% (Riot Platforms (RIOT) reports beneficial ownership of 14% in Bitfarms)
- CABA +6.8% (reports Initial Clinical Data from Phase 1/2 RESET-Myositis and RESET-SLE Trials of CABA-201; also releases presentation on CABA-201)
- VXRT +5.3% (receives BARDA-funded Project NextGen award valued up to $453 mln)
- IVVD +2.9% (announces that VYD222 shows continued in vitro neutralization activity in pseudovirus assays designed to represent the predominant emerging variants of SARS-CoV-2, including the KP.1.1 FLiRT and KP.3 variants)
- CIM +2.8% (increases dividend)
- IRON +2.8% (presents positive clinical data across portfolio at the European Hematology Association 2024 Congress)
- STTK +2.2% (Announces Updated Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine)
- SNDX +1.4% (Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress)
- TSLA +1.3% (shareholders approve moving incorporation to Texas; approve CEO $56 bln pay package)
- ZURA +1.1% (presents data for the tibulizumab (ZB-106) program at EULAR 2024)
- ARM +1% (to join the Nasdaq-100 Index beginning June 24, 2024)
Analyst comments:
- ZS +2% (upgraded to Overweight from Neutral at JP Morgan)
- SHOP +1.9% (upgraded to Outperform from In-line at Evercore ISI)
- VRNS +1.9% (upgraded to Overweight from Neutral at JP Morgan)
- HAS +1.1% (upgraded to Buy from Neutral at BofA Securities)